anti drd2 Search Results


93
Alomone Labs drd2
Drd2, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/drd2/product/Alomone Labs
Average 93 stars, based on 1 article reviews
drd2 - by Bioz Stars, 2026-04
93/100 stars
  Buy from Supplier

92
Bioss drd2 polyclonal antibody
Drd2 Polyclonal Antibody, supplied by Bioss, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/drd2 polyclonal antibody/product/Bioss
Average 92 stars, based on 1 article reviews
drd2 polyclonal antibody - by Bioz Stars, 2026-04
92/100 stars
  Buy from Supplier

90
Alomone Labs anti d2 dopamine receptor fitc antibody solution
Anti D2 Dopamine Receptor Fitc Antibody Solution, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti d2 dopamine receptor fitc antibody solution/product/Alomone Labs
Average 90 stars, based on 1 article reviews
anti d2 dopamine receptor fitc antibody solution - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

90
Boster Bio drd2
Figure 4 – Immmunoreactivity staining of different markers in ectopic lesions in different groups. (A) Representative immunostaining of ADRB2 in endometrium in CONTROL and SHAM mice and in ectopic endometrium in STRESSED and UNSTRESSED mice. ADRB2 and <t>DRD2</t> immunoreactivity was both seen primarily in glandular epithelial cells and was localized in the cytoplasm. Scale bar = 125 μm. (B) Representative immunostaining of DRD2, VEGF, CD31, CD41, F4/80, PCNA and α-SMA in the ectopic lesions in UNSTRESSED and STRESSED groups. VEGF immunoreactivity was seen primarily in glandular epithelial cells and was localized in the cytoplasm. CD31 immunostainings were seen mostly in vascular endothelial cells. CD41 shows the extent of platelet aggregation and F4/80 immunoreactivity represents the extent of macrophage infiltration. PCNA immunoreactivity was seen both in glandular epithelial cells and stromal cells were localized in the cell nucleus, but the change of immunoreactivity in glandular epithelial cells was more obvious. α-SMA staining were seen mostly in the stromal component of the ectopic lesions. Scale bar = 125 μm. Mice in stressed (STRS) and unstressed (UNSTRS) groups had undergone endometriosis-inducing surgery, while mice the SHAM group underwent non-endometriosis-inducing surgery. Mice in unstressed (UNSTRS), SHAM and control (CTL) groups were not exposed to stress.
Drd2, supplied by Boster Bio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/drd2/product/Boster Bio
Average 90 stars, based on 1 article reviews
drd2 - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

93
Alomone Labs rabbit polyclonal antibody
Figure 4 – Immmunoreactivity staining of different markers in ectopic lesions in different groups. (A) Representative immunostaining of ADRB2 in endometrium in CONTROL and SHAM mice and in ectopic endometrium in STRESSED and UNSTRESSED mice. ADRB2 and <t>DRD2</t> immunoreactivity was both seen primarily in glandular epithelial cells and was localized in the cytoplasm. Scale bar = 125 μm. (B) Representative immunostaining of DRD2, VEGF, CD31, CD41, F4/80, PCNA and α-SMA in the ectopic lesions in UNSTRESSED and STRESSED groups. VEGF immunoreactivity was seen primarily in glandular epithelial cells and was localized in the cytoplasm. CD31 immunostainings were seen mostly in vascular endothelial cells. CD41 shows the extent of platelet aggregation and F4/80 immunoreactivity represents the extent of macrophage infiltration. PCNA immunoreactivity was seen both in glandular epithelial cells and stromal cells were localized in the cell nucleus, but the change of immunoreactivity in glandular epithelial cells was more obvious. α-SMA staining were seen mostly in the stromal component of the ectopic lesions. Scale bar = 125 μm. Mice in stressed (STRS) and unstressed (UNSTRS) groups had undergone endometriosis-inducing surgery, while mice the SHAM group underwent non-endometriosis-inducing surgery. Mice in unstressed (UNSTRS), SHAM and control (CTL) groups were not exposed to stress.
Rabbit Polyclonal Antibody, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rabbit polyclonal antibody/product/Alomone Labs
Average 93 stars, based on 1 article reviews
rabbit polyclonal antibody - by Bioz Stars, 2026-04
93/100 stars
  Buy from Supplier

90
ABclonal Biotechnology anti-drd2 rabbit pab a12930
<t>Drd2</t> immunohistochemistry in adult zebrafish brain. On the right, drd2 protein distribution in transverse sections of zebrafish brain, ankk1 +/+ and ankk1 27 ins/ 27 ins . On the left, schematic depiction of zebrafish brain, transversal section [adapted from ]. (a–e) Boxes on the schematic depictions represent the region of the brain showed by the corresponding immunohistochemistry on the right; (a’–b”) forebrain drd2 staining; (c’–e”) midbrain drd2 staining. Scale bars: (c”,d”,e’) , 50 mm; (a’–e’) , 100 mm; (b”) , 200 mm. Arrows indicate anti-drd2 positive cells.
Anti Drd2 Rabbit Pab A12930, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti-drd2 rabbit pab a12930/product/ABclonal Biotechnology
Average 90 stars, based on 1 article reviews
anti-drd2 rabbit pab a12930 - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

90
Abbiotec Inc rabbit anti-drd2 receptor antibody #251384
Loss-of-Function and Gain-of-Function Studies of the <t>Dopamine</t> <t>D2</t> <t>Receptor</t> <t>DRD2</t> in MIN6 Cells The effects of DPD and dopamine (DA) in control (A, B, C, G) and Drd2 -knockdown (D, E, F) or Drd2 -overexpressing (H, I) MIN6 cells. (A) The number of MIN6 cells per well after 4 days of chemical treatment (days 3–7). Dopamine treatment decreased the number of cells, whereas DPD or cAMP treatment increased the number of MIN6 cells (five independent experiments, each with three to six replicates). (B) DPD increased proliferation of MIN6 cells revealed by EdU incorporation (48 hr) assay (four independent experiments, each with four replicates). (C) Relative cAMP levels after 6 hr of chemical treatment on day 3. DPD increased intracellular cAMP levels, whereas dopamine decreased intracellular cAMP levels, and DPD reversed the dopamine-mediated decrease. (D–F) Drd2 knockdown increased cAMP levels and phenocopied DPD effects. (D) Upper panel: a schematic of the lentiviral vector used for Drd2 shRNA- mRFP expression. Lower panel: fluorescence and transmission images of the Drd2 -knockdown MIN6 cells (D2KD). (E) D2KD cells showed a partial decrease in Drd2 expression (two independent experiments, each with three replicates). (F) Responses of D2KD cells to dopamine chemicals. DPD increased cell number for 9 days culture, but not in D2KD cells. The effect of dopamine decreased in knockdown cells (four independent experiments, each with four replicates). (G–I) Dopamine treatment of wild-type (G) or Drd2 -overexpressing (I) MIN6 cells on days 3–7. Dopamine dose-dependently increased the number of apoptotic cells (G) (three independent experiments, each with four replicates). Upper panel in (H) shows a schematic of the FLAG-tagged Drd2- expressing vector, and lower panel shows RT-PCR analysis of the exogenously overexpressed Drd2 in MIN6 cells. MIN6 cells overexpressing Drd2 (D2-OE) showed increased sensitivity to dopamine. Up to 37% of the cells became apoptotic after treatment with 10 μM dopamine (I) (three independent experiments, each with three replicates). ∗∗ p < 0.01, ∗ p < 0.05 compared with control DMSO-treated cells. Data represent mean ± SD. Student's t test. Scale bar, 100 μm.
Rabbit Anti Drd2 Receptor Antibody #251384, supplied by Abbiotec Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rabbit anti-drd2 receptor antibody #251384/product/Abbiotec Inc
Average 90 stars, based on 1 article reviews
rabbit anti-drd2 receptor antibody #251384 - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

90
ABclonal Biotechnology anti-drd-2
Loss-of-Function and Gain-of-Function Studies of the <t>Dopamine</t> <t>D2</t> <t>Receptor</t> <t>DRD2</t> in MIN6 Cells The effects of DPD and dopamine (DA) in control (A, B, C, G) and Drd2 -knockdown (D, E, F) or Drd2 -overexpressing (H, I) MIN6 cells. (A) The number of MIN6 cells per well after 4 days of chemical treatment (days 3–7). Dopamine treatment decreased the number of cells, whereas DPD or cAMP treatment increased the number of MIN6 cells (five independent experiments, each with three to six replicates). (B) DPD increased proliferation of MIN6 cells revealed by EdU incorporation (48 hr) assay (four independent experiments, each with four replicates). (C) Relative cAMP levels after 6 hr of chemical treatment on day 3. DPD increased intracellular cAMP levels, whereas dopamine decreased intracellular cAMP levels, and DPD reversed the dopamine-mediated decrease. (D–F) Drd2 knockdown increased cAMP levels and phenocopied DPD effects. (D) Upper panel: a schematic of the lentiviral vector used for Drd2 shRNA- mRFP expression. Lower panel: fluorescence and transmission images of the Drd2 -knockdown MIN6 cells (D2KD). (E) D2KD cells showed a partial decrease in Drd2 expression (two independent experiments, each with three replicates). (F) Responses of D2KD cells to dopamine chemicals. DPD increased cell number for 9 days culture, but not in D2KD cells. The effect of dopamine decreased in knockdown cells (four independent experiments, each with four replicates). (G–I) Dopamine treatment of wild-type (G) or Drd2 -overexpressing (I) MIN6 cells on days 3–7. Dopamine dose-dependently increased the number of apoptotic cells (G) (three independent experiments, each with four replicates). Upper panel in (H) shows a schematic of the FLAG-tagged Drd2- expressing vector, and lower panel shows RT-PCR analysis of the exogenously overexpressed Drd2 in MIN6 cells. MIN6 cells overexpressing Drd2 (D2-OE) showed increased sensitivity to dopamine. Up to 37% of the cells became apoptotic after treatment with 10 μM dopamine (I) (three independent experiments, each with three replicates). ∗∗ p < 0.01, ∗ p < 0.05 compared with control DMSO-treated cells. Data represent mean ± SD. Student's t test. Scale bar, 100 μm.
Anti Drd 2, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti-drd-2/product/ABclonal Biotechnology
Average 90 stars, based on 1 article reviews
anti-drd-2 - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

90
NeuroMab mouse anti-drd2
Loss-of-Function and Gain-of-Function Studies of the <t>Dopamine</t> <t>D2</t> <t>Receptor</t> <t>DRD2</t> in MIN6 Cells The effects of DPD and dopamine (DA) in control (A, B, C, G) and Drd2 -knockdown (D, E, F) or Drd2 -overexpressing (H, I) MIN6 cells. (A) The number of MIN6 cells per well after 4 days of chemical treatment (days 3–7). Dopamine treatment decreased the number of cells, whereas DPD or cAMP treatment increased the number of MIN6 cells (five independent experiments, each with three to six replicates). (B) DPD increased proliferation of MIN6 cells revealed by EdU incorporation (48 hr) assay (four independent experiments, each with four replicates). (C) Relative cAMP levels after 6 hr of chemical treatment on day 3. DPD increased intracellular cAMP levels, whereas dopamine decreased intracellular cAMP levels, and DPD reversed the dopamine-mediated decrease. (D–F) Drd2 knockdown increased cAMP levels and phenocopied DPD effects. (D) Upper panel: a schematic of the lentiviral vector used for Drd2 shRNA- mRFP expression. Lower panel: fluorescence and transmission images of the Drd2 -knockdown MIN6 cells (D2KD). (E) D2KD cells showed a partial decrease in Drd2 expression (two independent experiments, each with three replicates). (F) Responses of D2KD cells to dopamine chemicals. DPD increased cell number for 9 days culture, but not in D2KD cells. The effect of dopamine decreased in knockdown cells (four independent experiments, each with four replicates). (G–I) Dopamine treatment of wild-type (G) or Drd2 -overexpressing (I) MIN6 cells on days 3–7. Dopamine dose-dependently increased the number of apoptotic cells (G) (three independent experiments, each with four replicates). Upper panel in (H) shows a schematic of the FLAG-tagged Drd2- expressing vector, and lower panel shows RT-PCR analysis of the exogenously overexpressed Drd2 in MIN6 cells. MIN6 cells overexpressing Drd2 (D2-OE) showed increased sensitivity to dopamine. Up to 37% of the cells became apoptotic after treatment with 10 μM dopamine (I) (three independent experiments, each with three replicates). ∗∗ p < 0.01, ∗ p < 0.05 compared with control DMSO-treated cells. Data represent mean ± SD. Student's t test. Scale bar, 100 μm.
Mouse Anti Drd2, supplied by NeuroMab, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse anti-drd2/product/NeuroMab
Average 90 stars, based on 1 article reviews
mouse anti-drd2 - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

90
Merck & Co rabbit anti-drd2
Loss-of-Function and Gain-of-Function Studies of the <t>Dopamine</t> <t>D2</t> <t>Receptor</t> <t>DRD2</t> in MIN6 Cells The effects of DPD and dopamine (DA) in control (A, B, C, G) and Drd2 -knockdown (D, E, F) or Drd2 -overexpressing (H, I) MIN6 cells. (A) The number of MIN6 cells per well after 4 days of chemical treatment (days 3–7). Dopamine treatment decreased the number of cells, whereas DPD or cAMP treatment increased the number of MIN6 cells (five independent experiments, each with three to six replicates). (B) DPD increased proliferation of MIN6 cells revealed by EdU incorporation (48 hr) assay (four independent experiments, each with four replicates). (C) Relative cAMP levels after 6 hr of chemical treatment on day 3. DPD increased intracellular cAMP levels, whereas dopamine decreased intracellular cAMP levels, and DPD reversed the dopamine-mediated decrease. (D–F) Drd2 knockdown increased cAMP levels and phenocopied DPD effects. (D) Upper panel: a schematic of the lentiviral vector used for Drd2 shRNA- mRFP expression. Lower panel: fluorescence and transmission images of the Drd2 -knockdown MIN6 cells (D2KD). (E) D2KD cells showed a partial decrease in Drd2 expression (two independent experiments, each with three replicates). (F) Responses of D2KD cells to dopamine chemicals. DPD increased cell number for 9 days culture, but not in D2KD cells. The effect of dopamine decreased in knockdown cells (four independent experiments, each with four replicates). (G–I) Dopamine treatment of wild-type (G) or Drd2 -overexpressing (I) MIN6 cells on days 3–7. Dopamine dose-dependently increased the number of apoptotic cells (G) (three independent experiments, each with four replicates). Upper panel in (H) shows a schematic of the FLAG-tagged Drd2- expressing vector, and lower panel shows RT-PCR analysis of the exogenously overexpressed Drd2 in MIN6 cells. MIN6 cells overexpressing Drd2 (D2-OE) showed increased sensitivity to dopamine. Up to 37% of the cells became apoptotic after treatment with 10 μM dopamine (I) (three independent experiments, each with three replicates). ∗∗ p < 0.01, ∗ p < 0.05 compared with control DMSO-treated cells. Data represent mean ± SD. Student's t test. Scale bar, 100 μm.
Rabbit Anti Drd2, supplied by Merck & Co, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rabbit anti-drd2/product/Merck & Co
Average 90 stars, based on 1 article reviews
rabbit anti-drd2 - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

90
Wanleibio anti-drd2
Loss-of-Function and Gain-of-Function Studies of the <t>Dopamine</t> <t>D2</t> <t>Receptor</t> <t>DRD2</t> in MIN6 Cells The effects of DPD and dopamine (DA) in control (A, B, C, G) and Drd2 -knockdown (D, E, F) or Drd2 -overexpressing (H, I) MIN6 cells. (A) The number of MIN6 cells per well after 4 days of chemical treatment (days 3–7). Dopamine treatment decreased the number of cells, whereas DPD or cAMP treatment increased the number of MIN6 cells (five independent experiments, each with three to six replicates). (B) DPD increased proliferation of MIN6 cells revealed by EdU incorporation (48 hr) assay (four independent experiments, each with four replicates). (C) Relative cAMP levels after 6 hr of chemical treatment on day 3. DPD increased intracellular cAMP levels, whereas dopamine decreased intracellular cAMP levels, and DPD reversed the dopamine-mediated decrease. (D–F) Drd2 knockdown increased cAMP levels and phenocopied DPD effects. (D) Upper panel: a schematic of the lentiviral vector used for Drd2 shRNA- mRFP expression. Lower panel: fluorescence and transmission images of the Drd2 -knockdown MIN6 cells (D2KD). (E) D2KD cells showed a partial decrease in Drd2 expression (two independent experiments, each with three replicates). (F) Responses of D2KD cells to dopamine chemicals. DPD increased cell number for 9 days culture, but not in D2KD cells. The effect of dopamine decreased in knockdown cells (four independent experiments, each with four replicates). (G–I) Dopamine treatment of wild-type (G) or Drd2 -overexpressing (I) MIN6 cells on days 3–7. Dopamine dose-dependently increased the number of apoptotic cells (G) (three independent experiments, each with four replicates). Upper panel in (H) shows a schematic of the FLAG-tagged Drd2- expressing vector, and lower panel shows RT-PCR analysis of the exogenously overexpressed Drd2 in MIN6 cells. MIN6 cells overexpressing Drd2 (D2-OE) showed increased sensitivity to dopamine. Up to 37% of the cells became apoptotic after treatment with 10 μM dopamine (I) (three independent experiments, each with three replicates). ∗∗ p < 0.01, ∗ p < 0.05 compared with control DMSO-treated cells. Data represent mean ± SD. Student's t test. Scale bar, 100 μm.
Anti Drd2, supplied by Wanleibio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti-drd2/product/Wanleibio
Average 90 stars, based on 1 article reviews
anti-drd2 - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

90
Genentech inc antibody rabbit anti-drd2
Loss-of-Function and Gain-of-Function Studies of the <t>Dopamine</t> <t>D2</t> <t>Receptor</t> <t>DRD2</t> in MIN6 Cells The effects of DPD and dopamine (DA) in control (A, B, C, G) and Drd2 -knockdown (D, E, F) or Drd2 -overexpressing (H, I) MIN6 cells. (A) The number of MIN6 cells per well after 4 days of chemical treatment (days 3–7). Dopamine treatment decreased the number of cells, whereas DPD or cAMP treatment increased the number of MIN6 cells (five independent experiments, each with three to six replicates). (B) DPD increased proliferation of MIN6 cells revealed by EdU incorporation (48 hr) assay (four independent experiments, each with four replicates). (C) Relative cAMP levels after 6 hr of chemical treatment on day 3. DPD increased intracellular cAMP levels, whereas dopamine decreased intracellular cAMP levels, and DPD reversed the dopamine-mediated decrease. (D–F) Drd2 knockdown increased cAMP levels and phenocopied DPD effects. (D) Upper panel: a schematic of the lentiviral vector used for Drd2 shRNA- mRFP expression. Lower panel: fluorescence and transmission images of the Drd2 -knockdown MIN6 cells (D2KD). (E) D2KD cells showed a partial decrease in Drd2 expression (two independent experiments, each with three replicates). (F) Responses of D2KD cells to dopamine chemicals. DPD increased cell number for 9 days culture, but not in D2KD cells. The effect of dopamine decreased in knockdown cells (four independent experiments, each with four replicates). (G–I) Dopamine treatment of wild-type (G) or Drd2 -overexpressing (I) MIN6 cells on days 3–7. Dopamine dose-dependently increased the number of apoptotic cells (G) (three independent experiments, each with four replicates). Upper panel in (H) shows a schematic of the FLAG-tagged Drd2- expressing vector, and lower panel shows RT-PCR analysis of the exogenously overexpressed Drd2 in MIN6 cells. MIN6 cells overexpressing Drd2 (D2-OE) showed increased sensitivity to dopamine. Up to 37% of the cells became apoptotic after treatment with 10 μM dopamine (I) (three independent experiments, each with three replicates). ∗∗ p < 0.01, ∗ p < 0.05 compared with control DMSO-treated cells. Data represent mean ± SD. Student's t test. Scale bar, 100 μm.
Antibody Rabbit Anti Drd2, supplied by Genentech inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/antibody rabbit anti-drd2/product/Genentech inc
Average 90 stars, based on 1 article reviews
antibody rabbit anti-drd2 - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

Image Search Results


Figure 4 – Immmunoreactivity staining of different markers in ectopic lesions in different groups. (A) Representative immunostaining of ADRB2 in endometrium in CONTROL and SHAM mice and in ectopic endometrium in STRESSED and UNSTRESSED mice. ADRB2 and DRD2 immunoreactivity was both seen primarily in glandular epithelial cells and was localized in the cytoplasm. Scale bar = 125 μm. (B) Representative immunostaining of DRD2, VEGF, CD31, CD41, F4/80, PCNA and α-SMA in the ectopic lesions in UNSTRESSED and STRESSED groups. VEGF immunoreactivity was seen primarily in glandular epithelial cells and was localized in the cytoplasm. CD31 immunostainings were seen mostly in vascular endothelial cells. CD41 shows the extent of platelet aggregation and F4/80 immunoreactivity represents the extent of macrophage infiltration. PCNA immunoreactivity was seen both in glandular epithelial cells and stromal cells were localized in the cell nucleus, but the change of immunoreactivity in glandular epithelial cells was more obvious. α-SMA staining were seen mostly in the stromal component of the ectopic lesions. Scale bar = 125 μm. Mice in stressed (STRS) and unstressed (UNSTRS) groups had undergone endometriosis-inducing surgery, while mice the SHAM group underwent non-endometriosis-inducing surgery. Mice in unstressed (UNSTRS), SHAM and control (CTL) groups were not exposed to stress.

Journal: Reproductive biomedicine online

Article Title: Social psychogenic stress promotes the development of endometriosis in mouse.

doi: 10.1016/j.rbmo.2016.11.012

Figure Lengend Snippet: Figure 4 – Immmunoreactivity staining of different markers in ectopic lesions in different groups. (A) Representative immunostaining of ADRB2 in endometrium in CONTROL and SHAM mice and in ectopic endometrium in STRESSED and UNSTRESSED mice. ADRB2 and DRD2 immunoreactivity was both seen primarily in glandular epithelial cells and was localized in the cytoplasm. Scale bar = 125 μm. (B) Representative immunostaining of DRD2, VEGF, CD31, CD41, F4/80, PCNA and α-SMA in the ectopic lesions in UNSTRESSED and STRESSED groups. VEGF immunoreactivity was seen primarily in glandular epithelial cells and was localized in the cytoplasm. CD31 immunostainings were seen mostly in vascular endothelial cells. CD41 shows the extent of platelet aggregation and F4/80 immunoreactivity represents the extent of macrophage infiltration. PCNA immunoreactivity was seen both in glandular epithelial cells and stromal cells were localized in the cell nucleus, but the change of immunoreactivity in glandular epithelial cells was more obvious. α-SMA staining were seen mostly in the stromal component of the ectopic lesions. Scale bar = 125 μm. Mice in stressed (STRS) and unstressed (UNSTRS) groups had undergone endometriosis-inducing surgery, while mice the SHAM group underwent non-endometriosis-inducing surgery. Mice in unstressed (UNSTRS), SHAM and control (CTL) groups were not exposed to stress.

Article Snippet: For negative controls, the immunoglobulin G (IgG) from the rabbit serum (Sigma, Darmstadt, Germany) was used instead of primary antibodies against ADRB2, DRD2, VEGF, CD31, CD41, α-SMA and PCNA except for F4/80, for which the IgG was from the rat serum (Boster, Wuhan, China) was used, all used at the same concentration with its corresponding primary antibody.

Techniques: Staining, Immunostaining, Control

Drd2 immunohistochemistry in adult zebrafish brain. On the right, drd2 protein distribution in transverse sections of zebrafish brain, ankk1 +/+ and ankk1 27 ins/ 27 ins . On the left, schematic depiction of zebrafish brain, transversal section [adapted from ]. (a–e) Boxes on the schematic depictions represent the region of the brain showed by the corresponding immunohistochemistry on the right; (a’–b”) forebrain drd2 staining; (c’–e”) midbrain drd2 staining. Scale bars: (c”,d”,e’) , 50 mm; (a’–e’) , 100 mm; (b”) , 200 mm. Arrows indicate anti-drd2 positive cells.

Journal: Frontiers in Neuroscience

Article Title: Ankk1 Loss of Function Disrupts Dopaminergic Pathways in Zebrafish

doi: 10.3389/fnins.2022.794653

Figure Lengend Snippet: Drd2 immunohistochemistry in adult zebrafish brain. On the right, drd2 protein distribution in transverse sections of zebrafish brain, ankk1 +/+ and ankk1 27 ins/ 27 ins . On the left, schematic depiction of zebrafish brain, transversal section [adapted from ]. (a–e) Boxes on the schematic depictions represent the region of the brain showed by the corresponding immunohistochemistry on the right; (a’–b”) forebrain drd2 staining; (c’–e”) midbrain drd2 staining. Scale bars: (c”,d”,e’) , 50 mm; (a’–e’) , 100 mm; (b”) , 200 mm. Arrows indicate anti-drd2 positive cells.

Article Snippet: Slides were subsequently incubated with anti-ankk1 Rabbit pAb (A16178, ABclonal), or anti-drd2 Rabbit pAb (A12930, ABclonal), 1:200 in BS, ON at 4°C.

Techniques: Immunohistochemistry, Staining

Loss-of-Function and Gain-of-Function Studies of the Dopamine D2 Receptor DRD2 in MIN6 Cells The effects of DPD and dopamine (DA) in control (A, B, C, G) and Drd2 -knockdown (D, E, F) or Drd2 -overexpressing (H, I) MIN6 cells. (A) The number of MIN6 cells per well after 4 days of chemical treatment (days 3–7). Dopamine treatment decreased the number of cells, whereas DPD or cAMP treatment increased the number of MIN6 cells (five independent experiments, each with three to six replicates). (B) DPD increased proliferation of MIN6 cells revealed by EdU incorporation (48 hr) assay (four independent experiments, each with four replicates). (C) Relative cAMP levels after 6 hr of chemical treatment on day 3. DPD increased intracellular cAMP levels, whereas dopamine decreased intracellular cAMP levels, and DPD reversed the dopamine-mediated decrease. (D–F) Drd2 knockdown increased cAMP levels and phenocopied DPD effects. (D) Upper panel: a schematic of the lentiviral vector used for Drd2 shRNA- mRFP expression. Lower panel: fluorescence and transmission images of the Drd2 -knockdown MIN6 cells (D2KD). (E) D2KD cells showed a partial decrease in Drd2 expression (two independent experiments, each with three replicates). (F) Responses of D2KD cells to dopamine chemicals. DPD increased cell number for 9 days culture, but not in D2KD cells. The effect of dopamine decreased in knockdown cells (four independent experiments, each with four replicates). (G–I) Dopamine treatment of wild-type (G) or Drd2 -overexpressing (I) MIN6 cells on days 3–7. Dopamine dose-dependently increased the number of apoptotic cells (G) (three independent experiments, each with four replicates). Upper panel in (H) shows a schematic of the FLAG-tagged Drd2- expressing vector, and lower panel shows RT-PCR analysis of the exogenously overexpressed Drd2 in MIN6 cells. MIN6 cells overexpressing Drd2 (D2-OE) showed increased sensitivity to dopamine. Up to 37% of the cells became apoptotic after treatment with 10 μM dopamine (I) (three independent experiments, each with three replicates). ∗∗ p < 0.01, ∗ p < 0.05 compared with control DMSO-treated cells. Data represent mean ± SD. Student's t test. Scale bar, 100 μm.

Journal: Stem Cell Reports

Article Title: Dopamine D2 Receptor-Mediated Regulation of Pancreatic β Cell Mass

doi: 10.1016/j.stemcr.2016.05.015

Figure Lengend Snippet: Loss-of-Function and Gain-of-Function Studies of the Dopamine D2 Receptor DRD2 in MIN6 Cells The effects of DPD and dopamine (DA) in control (A, B, C, G) and Drd2 -knockdown (D, E, F) or Drd2 -overexpressing (H, I) MIN6 cells. (A) The number of MIN6 cells per well after 4 days of chemical treatment (days 3–7). Dopamine treatment decreased the number of cells, whereas DPD or cAMP treatment increased the number of MIN6 cells (five independent experiments, each with three to six replicates). (B) DPD increased proliferation of MIN6 cells revealed by EdU incorporation (48 hr) assay (four independent experiments, each with four replicates). (C) Relative cAMP levels after 6 hr of chemical treatment on day 3. DPD increased intracellular cAMP levels, whereas dopamine decreased intracellular cAMP levels, and DPD reversed the dopamine-mediated decrease. (D–F) Drd2 knockdown increased cAMP levels and phenocopied DPD effects. (D) Upper panel: a schematic of the lentiviral vector used for Drd2 shRNA- mRFP expression. Lower panel: fluorescence and transmission images of the Drd2 -knockdown MIN6 cells (D2KD). (E) D2KD cells showed a partial decrease in Drd2 expression (two independent experiments, each with three replicates). (F) Responses of D2KD cells to dopamine chemicals. DPD increased cell number for 9 days culture, but not in D2KD cells. The effect of dopamine decreased in knockdown cells (four independent experiments, each with four replicates). (G–I) Dopamine treatment of wild-type (G) or Drd2 -overexpressing (I) MIN6 cells on days 3–7. Dopamine dose-dependently increased the number of apoptotic cells (G) (three independent experiments, each with four replicates). Upper panel in (H) shows a schematic of the FLAG-tagged Drd2- expressing vector, and lower panel shows RT-PCR analysis of the exogenously overexpressed Drd2 in MIN6 cells. MIN6 cells overexpressing Drd2 (D2-OE) showed increased sensitivity to dopamine. Up to 37% of the cells became apoptotic after treatment with 10 μM dopamine (I) (three independent experiments, each with three replicates). ∗∗ p < 0.01, ∗ p < 0.05 compared with control DMSO-treated cells. Data represent mean ± SD. Student's t test. Scale bar, 100 μm.

Article Snippet: Primary antibodies used were: rabbit anti-DRD2 receptor antibody (1:500; ABBIOTEC, #251384) or mouse monoclonal (7FG-G5-A2) to ADORA2A (1:500; Abcam, #ab79714).

Techniques: Control, Knockdown, Plasmid Preparation, shRNA, Expressing, Fluorescence, Transmission Assay, Reverse Transcription Polymerase Chain Reaction

Synergistic Effects of NECA, an ADORA2A Agonist, and DPD on β Cell Proliferation and Cell Death through Interaction between DRD2 and ADORA2A (A and B) DRD2 and ADORA2A are expressed and form heterodimer in dissociated mouse pancreatic β cells. (A–A″) Islets were dissociated and Duolink assay was performed immediately after dissociation. (B) Co-immunoprecipitates of the dissociated islet cells using anti-DRD2 (IP-D2), anti-ADORA2A (IP-A2A), or mouse IgG (mIgG) antibody were immunoblotted with anti-ADORA2A (IB-A2A) or anti-DRD2 Ab (IB-D2), respectively. The results indicated that DRD2 and ADORA2A formed a heterodimer. (C–G) DRD2-ADORA2A dimerization states detected by Duolink assay were changed by dopamine (DA), DPD, or NECA, an ADORA2A agonist (C–F′). Dissociated islet cell cultures on day 3 were treated with chemicals for 6 hr and subjected to Duolink assay. (G) DRD2-ADORA2A heterodimer formation was suppressed by DPD or NECA, and enhanced by dopamine. (H–J) The effect of NECA on β cell proliferation was examined using islet dissociation cultures. (H) The number of Ins + cells after 4 days of chemical treatment (days 3–7) were counted and was increased by NECA treatment. The dopamine-mediated reduction in the number of β cells was reversed by treatment with NECA or DPD. (I) The number of EdU + among the Ins + cells after 4 days of chemical treatment (days 3–7) were counted. EdU incorporation (48 hr) in β cells was increased by NECA treatment. Decreased β cell proliferation was reversed by treatment with NECA or DPD. (J) β cell apoptosis was assessed after 2 days of chemical treatment (days 3–5). The number of apoptotic β cells was decreased by treatment with NECA or DPD. Dopamine-triggered apoptosis was rescued by DPD but not by NECA. (K) Schematic of crosstalk between dopamine-DRD2 and adenosine-ADORA2A through heterodimer formation. Data represent mean ± SD. All data are obtained from three independent experiments, each with three replicates. ∗∗ p < 0.01, ∗ p < 0.05 compared with control (open bars), Student's t test.

Journal: Stem Cell Reports

Article Title: Dopamine D2 Receptor-Mediated Regulation of Pancreatic β Cell Mass

doi: 10.1016/j.stemcr.2016.05.015

Figure Lengend Snippet: Synergistic Effects of NECA, an ADORA2A Agonist, and DPD on β Cell Proliferation and Cell Death through Interaction between DRD2 and ADORA2A (A and B) DRD2 and ADORA2A are expressed and form heterodimer in dissociated mouse pancreatic β cells. (A–A″) Islets were dissociated and Duolink assay was performed immediately after dissociation. (B) Co-immunoprecipitates of the dissociated islet cells using anti-DRD2 (IP-D2), anti-ADORA2A (IP-A2A), or mouse IgG (mIgG) antibody were immunoblotted with anti-ADORA2A (IB-A2A) or anti-DRD2 Ab (IB-D2), respectively. The results indicated that DRD2 and ADORA2A formed a heterodimer. (C–G) DRD2-ADORA2A dimerization states detected by Duolink assay were changed by dopamine (DA), DPD, or NECA, an ADORA2A agonist (C–F′). Dissociated islet cell cultures on day 3 were treated with chemicals for 6 hr and subjected to Duolink assay. (G) DRD2-ADORA2A heterodimer formation was suppressed by DPD or NECA, and enhanced by dopamine. (H–J) The effect of NECA on β cell proliferation was examined using islet dissociation cultures. (H) The number of Ins + cells after 4 days of chemical treatment (days 3–7) were counted and was increased by NECA treatment. The dopamine-mediated reduction in the number of β cells was reversed by treatment with NECA or DPD. (I) The number of EdU + among the Ins + cells after 4 days of chemical treatment (days 3–7) were counted. EdU incorporation (48 hr) in β cells was increased by NECA treatment. Decreased β cell proliferation was reversed by treatment with NECA or DPD. (J) β cell apoptosis was assessed after 2 days of chemical treatment (days 3–5). The number of apoptotic β cells was decreased by treatment with NECA or DPD. Dopamine-triggered apoptosis was rescued by DPD but not by NECA. (K) Schematic of crosstalk between dopamine-DRD2 and adenosine-ADORA2A through heterodimer formation. Data represent mean ± SD. All data are obtained from three independent experiments, each with three replicates. ∗∗ p < 0.01, ∗ p < 0.05 compared with control (open bars), Student's t test.

Article Snippet: Primary antibodies used were: rabbit anti-DRD2 receptor antibody (1:500; ABBIOTEC, #251384) or mouse monoclonal (7FG-G5-A2) to ADORA2A (1:500; Abcam, #ab79714).

Techniques: Control